L&C Bio Co. Ltd Cash Flow Conversion Efficiency

Latest as of September 2025: 0.014x

L&C Bio Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, L&C Bio Co. Ltd (290650) has a cash flow conversion efficiency ratio of 0.014x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩3.79 Billion ≈ $2.57 Million USD) by net assets (₩266.71 Billion ≈ $180.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of L&C Bio Co. Ltd (2015–2024)

Cash flow conversion efficiency of L&C Bio Co. Ltd from 2015 to 2024. This chart illustrates how L&C Bio Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for L&C Bio Co. Ltd for real-time trading data and today's change.

L&C Bio Co. Ltd Cash Flow Conversion Ratio Explained

L&C Bio Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

L&C Bio Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of L&C Bio Co. Ltd ranked by their cash flow conversion efficiency. Also see 290650 company net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Bank7 Corp NASDAQ:BSVN	0.064x
Boston Omaha Corp NYSE:BOC	0.008x
Shanghai Lianming Machinery Co Ltd SHG:603006	0.006x
Simei Media Co Ltd SHE:002712	-0.018x
Apex International Co Ltd TW:4927	0.007x
Geron Co Ltd SHE:002722	-0.018x
Israel Land Development Company Co Ltd TA:ILDC	0.013x
Shanghai Rychen Technologies Co. Ltd. A SHE:301273	N/A

Annual Cash Flow Conversion Efficiency for L&C Bio Co. Ltd (2015–2024)

The table below shows the annual cash flow conversion efficiency of L&C Bio Co. Ltd from 2015 to 2024. Review 290650 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩284.35 Billion ≈ $192.70 Million	₩-8.57 Billion ≈ $-5.81 Million	-0.030x	+63.51%
2023-12-31	₩146.94 Billion ≈ $99.58 Million	₩-12.13 Billion ≈ $-8.22 Million	-0.083x	-33.11%
2022-12-31	₩97.95 Billion ≈ $66.38 Million	₩-6.08 Billion ≈ $-4.12 Million	-0.062x	-148.35%
2021-12-31	₩85.02 Billion ≈ $57.62 Million	₩10.91 Billion ≈ $7.39 Million	0.128x	-0.05%
2020-12-31	₩57.81 Billion ≈ $39.17 Million	₩7.42 Billion ≈ $5.03 Million	0.128x	+16.12%
2019-12-31	₩58.18 Billion ≈ $39.43 Million	₩6.43 Billion ≈ $4.36 Million	0.111x	+50.78%
2018-12-31	₩52.46 Billion ≈ $35.55 Million	₩3.85 Billion ≈ $2.61 Million	0.073x	-67.72%
2017-12-31	₩16.81 Billion ≈ $11.39 Million	₩3.82 Billion ≈ $2.59 Million	0.227x	+1327.62%
2016-12-31	₩10.02 Billion ≈ $6.79 Million	₩-185.35 Million ≈ $-125.61K	-0.018x	+94.55%
2015-12-31	₩3.91 Billion ≈ $2.65 Million	₩-1.33 Billion ≈ $-899.78K	-0.339x	--

About L&C Bio Co. Ltd

KQ:290650 Korea Medical Devices

Market Cap

$402.08 Million

₩593.31 Billion KRW

Market Cap Rank

#13012 Global

#372 in Korea

Share Price

₩24100.00

Change (1 day)

-4.93%

52-Week Range

₩23800.00 - ₩118300.00

All Time High

₩118300.00